drugset / Trial / NCT00004682

Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia Gravis

NCT00004682

Terminated 100 enrolled University of Texas
RandomizedTreatment

Summary

OBJECTIVES: I. Determine whether intravenous immunoglobulin is an effective therapy for patients with mild or moderate myasthenia gravis.

Timeline

Start
1995-03
Primary completion
Completion
1999-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic Intravenous

Indications